PMID- 18803425
OWN - NLM
STAT- MEDLINE
DCOM- 20081124
LR  - 20191111
IS  - 1177-1062 (Print)
IS  - 1177-1062 (Linking)
VI  - 12
IP  - 5
DP  - 2008
TI  - Clinical application of array-based comparative genomic hybridization for the 
      identification of prognostically important genetic alterations in chronic 
      lymphocytic leukemia.
PG  - 271-80
AB  - Genomic aberrations have increasingly gained attention as prognostic markers in 
      B-cell chronic lymphocytic leukemia (CLL). Fluorescence in situ hybridization 
      (FISH) has improved the detection rate of genomic alterations in CLL from 
      approximately 50% using conventional cytogenetics to greater than 80%. More 
      recently, array comparative genomic hybridization (CGH) has gained popularity as 
      a clinical tool that can be applied to detect genomic gains and losses of 
      prognostic importance in CLL. Array CGH and FISH are particularly useful in CLL 
      because genomic gains and losses are key events with both biologic and prognostic 
      significance, while balanced translocations have limited prognostic value. 
      Although FISH has a higher technical sensitivity, it requires separate, targeted 
      hybridizations for the detection of alterations at genomic loci of interest. 
      Array CGH, on the other hand, has the ability to provide a genome-wide survey of 
      genomic aberrations with a single hybridization reaction. Array CGH is expanding 
      the known genomic regions of importance in CLL and allows these regions to be 
      evaluated in the context of a genome-wide perspective. Ongoing clinical trials 
      are evaluating the use of genomic aberrations as tools for risk-stratifying 
      patients for therapy, thus increasing the need for reliable and high-yield 
      methods to detect these genomic changes. In this review, we consider the use of 
      array CGH as a clinical tool for the identification of genomic alterations with 
      prognostic significance in CLL, and suggest ways to integrate this test into the 
      clinical molecular diagnostic laboratory work flow.
FAU - Higgins, Russell A
AU  - Higgins RA
AD  - Department of Pathology, The University of Texas Health Science Center at San 
      Antonio, San Antonio, Texas, USA.
FAU - Gunn, Shelly R
AU  - Gunn SR
FAU - Robetorye, Ryan S
AU  - Robetorye RS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Mol Diagn Ther
JT  - Molecular diagnosis & therapy
JID - 101264260
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Chromosome Aberrations
MH  - Chromosome Mapping
MH  - Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/*genetics
MH  - Microarray Analysis/*methods
MH  - Molecular Diagnostic Techniques
MH  - Nucleic Acid Hybridization/*methods
MH  - Prognosis
MH  - Sensitivity and Specificity
RF  - 51
EDAT- 2008/09/23 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/09/23 09:00
PHST- 2008/09/23 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/23 09:00 [entrez]
AID - 1251 [pii]
AID - 10.1007/BF03256292 [doi]
PST - ppublish
SO  - Mol Diagn Ther. 2008;12(5):271-80. doi: 10.1007/BF03256292.